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Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative
disorder caused by a trinucleotide repeat expansion in the Huntingtin gene. As
disease-modifying therapies for HD are being developed, peripheral blood cells may be
used to indicate disease progression and to monitor treatment response. In order to
investigate whether gene expression changes can be found in the blood of individuals
with HD that distinguish them from healthy controls, we performed transcriptome analysis
by next-generation sequencing (RNA-seq). We detected a gene expression signature
consistent with dysregulation of immune-related functions and inflammatory response
in peripheral blood from HD cases vs. controls, including induction of the interferon
response genes, IFITM3, IFI6 and IRF7. Our results suggest that it is possible to detect
gene expression changes in blood samples from individuals with HD, which may reflect
the immune pathology associated with the disease.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease that commonly
presents in mid-life with a triad of motor, cognitive, and psychiatric symptoms. HD is caused by a
CAG trinucleotide repeat expansion in the first exon of theHuntingtin gene on chromosome 4 (1).
Although the gene was identifiedmore than 20 years ago, the pathophysiology of HD is still unclear.
Huntingtin (HTT) is a ubiquitously expressed essential protein that is believed to acquire a toxic
gain of function from the expanded polyglutamine stretch in the N-terminal part of the protein
(2). Neurons are particularly vulnerable to mutant huntingtin (mHTT), but there is increasing
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evidence that the immune system is also affected. Microglia,
the innate immune cells of the central nervous system (CNS),
are activated even before the onset of symptoms in HD (3),
and the degree of microglial activation correlates with disease
severity (4). The cerebrospinal fluid and striatum of people
with HD exhibit abnormal immune activation, suggesting that
immune dysfunction plays a role in HD pathogenesis (5).
Loss of Foxp1-mediated gene regulation may contribute to
the immune dysfunction in HD (6). Notably, leukocytes in
peripheral blood express mHTT, show migration deficits and
are pathologically hyperactive (5, 7–9). The levels of mHTT in
circulatingmonocytes and T cells are significantly associated with
disease burden scores and caudate atrophy rates in individuals
with HD (9).
The inflammatory changes detected in peripheral blood have
been suggested to be shared between blood and brain in HD
(10, 11). In fact, specific genomic profiles have also been
identified in the blood of individuals with stroke, multiple
sclerosis, and many other neurological diseases (12). Using two
different microarray platforms, more than 300 mRNAs showed
significantly altered expression in HD blood samples compared
with controls (13). Expression of a subset of 12 genes clearly
distinguished individuals with HD from healthy controls and
correlated with disease progression (13). However, these findings
were not confirmed in a follow-up study that identified the
Immediate Early Response 3 gene as a promising candidate (14).
An increase in myeloperoxidase/white blood cell ratio was also
detected in the blood of HD cases (15). Here, we have used next-
generation sequencing to analyze differential RNA expression
in blood samples from individuals with HD and age-matched
controls from a single site in Germany in order to provide
additional evidence for a blood signature of the disease.
RESULTS
Peripheral venous blood was collected from HD cases, including
two pre-symptomatic HD mutation carriers and 9 symptomatic
HD cases, and 8 age-matched controls without CNS disease
(average age 55 and 58 years, respectively; p = 0.26 Student’s t-
test). The number of CAG repeats in the HD cases was between
41 and 43 (average = 42.0, stdev = 0.63). RNA was isolated and
analyzed using deep sequencing of RNA transcripts (RNA-seq,
see section Methods). The data were examined for differential
gene expression, as well as for differential expression of individual
exons and transcript isoforms.
RNA-seq Gene Expression Analysis
Values of expression were derived for transcripts
(Supplementary Table 1; see section Methods). A total of
213 genes were found to be significantly upregulated, and 61
genes were significantly downregulated in HD cases vs. controls
(q-value < 0.05; Figure 1). Gene Ontology (GO) enrichment
analysis of these gene sets using all detected genes as background
(23,604 genes) was performed using GOstat [using goa_human
annotations; (17)]. Notably, immune-related functions were
found in the set of upregulated genes. A total of 38 genes (545
in background) were related to immune response (p-value =
2e-35; Bonferroni corrected hereafter), and 20 genes (270 in
background) were related to inflammatory response (p-value =
3e-8) with some overlap between the sets. In contrast, the only
GO term found to be enriched in the downregulated genes was
hemoglobin complex (associated to three genes HBD, HBG1
and HBG2 vs. 11 in background; p-value = 0.004). In Table 1,
we summarize how our dataset of dysregulated genes in HD
peripheral blood compares to previous studies using blood and
CNS tissue from HD cases (10, 11, 13, 14, 18–22). Importantly,
the expression of two interferon-induced genes, IFITM3 and IFI6
(G1P3), as well as CD274 (PDL1) and NDST1 was upregulated
in both peripheral blood (our study) and choroid plexus (22)
of HD cases (Figure 2). The upregulation of NCF4 and PROK2
in HD peripheral blood cells was shared between our study
and Mastrokolias et al. (19) (Figure 2). Interestingly, we found
more overlap between studies for upregulated genes than for
downregulated genes (Figure 2).
RNA-seq Exon Expression Analysis
One of the strengths of the RNA-seq data is that it allows for
the analysis of differential expression at the level of independent
exons. In order to identify exons that are differentially expressed
in HD cases vs. controls, we evaluated the expression of a total
of 196,877 exons from 25,897 transcripts. Then, we selected
differentially expressed exons having more than 50 reads in
control samples, and at least five HD cases with z-scores > 4
(upregulation) or at least five HD cases with z-scores < −4
(downregulation). According to this selection procedure, we
identified 38 upregulated exons and 75 downregulated exons
from 107 transcripts (Supplementary Table 2). Using the same
selection procedure on 1,000 randomized datasets, we estimated
a p-value of 0.053 for the selection of 113 or more exons.
Consistently, we did not find significant differential expression of
gene transcript isoforms between HD cases and controls [using
MISO (23), see section Methods for details].
DISCUSSION
The study of gene expression in the peripheral blood of
individuals with HD has produced controversial results. The
first study in peripheral blood using oligonucleotide microarrays
found 322 differentially expressed (mostly upregulated) genes
in five pre-symptomatic and 12 manifest HD cases vs. 14
controls (13). This study presented a selection of 12 marker
genes upregulated in the blood of HD cases, of which seven
were also upregulated in post-mortem HD brain samples.
However, a subsequent study failed to replicate these findings
and detected only a modest increase in the expression of
the immediate early gene IER3 in the blood of 12 HD cases
vs. 10 controls (14). A quantitative PCR study in peripheral
blood leukocytes from four pre-symptomatic and 16 manifest
HD cases vs. 20 controls detected four downregulated genes
involved in metabolism and oxidative stress (18), none of
which were regulated in our study. However, we observed
increased expression of IL1B and genes involved in TNF
signaling similar to the findings of Runne et al. (14) in HD
peripheral blood cells, suggesting a proinflammatory profile.
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FIGURE 1 | Differential expression of 274 genes. The heatmap represents the expression values of 274 genes with significant differential expression in peripheral
blood of individuals with HD compared to controls (q-value < 0.05). The values are z-scores based on the log2 (FPKM) values, with 0 FPKM values set to 0.01, and
modified to account for outliers following (16). Labels at the bottom indicate sample type: controls to the left (CO_), HD to the right (HD_). The dendrogram indicates
(Continued)
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FIGURE 1 | results of hierarchically clustering the genes according to their expression values. Genes upregulated or downregulated in HD with respect to controls are
indicated with magenta and green boxes, respectively. Gene labels in orange indicate genes with functions related to inflammation or immune response (see text for
details); all of these genes are upregulated.
TABLE 1 | Comparison of our dataset of dysregulated genes in HD with gene sets from relevant studies.
Study Sample Transcriptome
analysis
Dataset/figure and table numbers
in referred publication
Overlap to our set of 213 up- and
61 down-regulated genes




Gene list not available
12 upregulated genes/Figure 2A No overlap
Runne et al. (14) PNAS HD blood Oligonucleotide
microarrays
19 upregulated genes/Table 3 1 gene (IL1B)
Chang et al. (18) PLoS
ONE
HD blood RT-PCR 4 downregulated genes No overlap
Hensman Moss et al. (11) HD blood RNA-seq Upregulated and downregulated
pathways
Comparison not possible
Mastrokolias et al. (19) Eur
J Hum Genet
HD blood DeepSAGE 99 up- and 68 down-regulated genes Gene list not available
10 up- and 10 down-regulated
genes/Table 2
3 upregulated genes (CYSTM1,
NCF4, PROK2) and 1 down-regulated
gene (NMT2)
5 validated upregulated genes 3 genes (ANXA3, CYSTM1, PROK2)




RNA-seq 101 up- and 29 down-regulated
genes/dataset S2 (FDR < 0.05)
5 upregulated genes (NAMPT,
KCNJ15, CASP5, RETN, MMP8)
Labadorf and Myers (21)
PLoS ONE
HD brain RNA-seq Alternative splice variants Comparison not possible







Gene modules Comparison not possible






Supplementary Table 2: 584 up- and
377 down-regulated genes (p-value
< 0.01)
14 up- and 2 down-regulated genes
(HBD, ZNF154)
More recently, RNA-seq was used to study gene expression in
peripheral blood from pre-manifest and manifest HD mutation
carriers. Interestingly, Miller et al. (20) identified TNF and IL1B
as the transcriptional regulators with the highest target gene
overlap with changes in the HD monocyte transcriptome when
comparing 30 HD cases with 33 controls. Five upregulated
genes (NAMPT, KCNJ15, CASP5, RETN, MMP8) in Miller
et al. (20) were shared with our data set. Immune pathways
were also enriched in a large DeepSAGE analysis of peripheral
blood from 27 pre-manifest and 64 manifest HD mutation
carriers vs. 33 controls (19). This important study identified
the five genes ZNF238, AQP9, CYSTM1, ANXA3, and PROK2
as HD biomarkers. Notably, ANXA3 (encoding Annexin A
3) and the circadian clock-controlled gene PROK2 (encoding
Prokineticin 2) were also induced in HD leukocytes in our
study. Likewise, both studies observed increased expression of
the NCF4 gene in HD leukocytes, which encodes the p40phox
subunit of the phagocyte NADPH oxidase that is crucial for the
innate immune response. Hensman Moss et al. (11) examined
peripheral blood from two large cohorts of 72 pre-manifest and
119 manifest HD cases and 49 controls by RNA-seq, which
revealed no differential expression of individual transcripts in
HD but a significant upregulation of immune-related pathways
in myeloid cells that replicated those in the HD brain. A
good overlap between blood and brain signatures in HD
was also observed in three transcriptomic studies of post-
mortem brain tissue demonstrating pronounced changes for
immune-related genes (10, 21, 24). When transcriptome-wide
Affymetrix microarrays were used to compare gene expression
in choroid plexus from three grade IV HD cases vs. six
controls (22), 14 upregulated genes and 2 downregulated
genes matched the differentially expressed genes that we
detected in HD leukocytes in this study. Most notably, the
interferon response genes, IFITM3 (encoding Interferon-induced
transmembrane protein 3), IFI6 (encoding Interferon alpha-
inducible protein 6), IRF7 (Interferon regulatory factor 7),
CD274 (encoding Programmed death-ligand 1), and NDST1
(encoding N-deacetylase-N-sulfotransferase-1) were induced in
both peripheral blood and choroid plexus in HD. IFITM3 has
recently been identified as a modulator of γ-secretase activity that
is associated with aging and Alzheimer’s disease (25). IFITM3
was also induced in activated microglia in response to β-amyloid
(26). The IRF7 gene has been associated with frontotemporal
lobar degeneration (27). Finally, enrichment of genes related
to immune response was detected in a study that assessed
longitudinal transcriptomic dysregulation in the peripheral blood
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FIGURE 2 | Comparison of our results with previous HD transcriptome analyses. Overlap of our set of dysregulated genes (N) with genes reported by Stopa et al. (22)
(S), Mastrokolias et al. (19) (Ma), and Miller et al. (20) (Mi). (A) downregulated genes; (B) upregulated genes. Our set overlaps with the previous three datasets while the
only overlap between the three previous datasets is the upregulation of VCAN in (19) and (20).
of transgenic monkeys with genomic integration of pathogenic
fragments of the human HTT gene (28).
In sum, our results suggest a peripheral blood signature
of HD that involves immune-related genes, in particular the
interferome. Further research and validation in large cohorts
with prospective longitudinal assessments by RNA-seq should
contribute to refine the set of genes that mirror HD in blood.
MATERIALS AND METHODS
Ethics Approval
All human experiments were performed in accordance with the
Declaration of Helsinki, and were approved by the regulatory
authorities (Ethikkommission der Charité Campus Mitte, Berlin,
Germany). All study participants gave written informed consent.
Study Participants
Subjects were genetically diagnosed with HD and examined by
experienced neurologists. Disease stage was determined based
on the UHDRS motor score and total functional capacity (29),
and the Folstein mini-mental state examination. Control subjects
were free of CNS disease. None of the study participants suffered
from inflammatory or infectious conditions.
RNA Extraction From Blood Samples
Peripheral venous blood was collected (3 × 10ml) from HD
patients and controls into tubes containing EDTA in the
mornings of 7th − 10th September 2009. RNA was immediately
extracted using the LeukoLOCKTM total RNA isolation system
according to the manufacturer’s protocol (Ambion, TX, USA).
All samples were analyzed separately and not pooled. Briefly, each
10ml blood sample was passed through a LeukoLOCKTM filter,
followed by flushing the filter with 3ml phosphate-buffered saline
(PBS), and subsequently with 3ml RNAlater R©. After removing
the residual RNAlater R© from the LeukoLOCKTM filter, the filter
was flushed with 2.5ml pH-adjusted Lysis/Binding solution. The
lysate was collected into 15ml tubes containing 2.5ml nuclease-
free water, followed by addition of 25 µl proteinase K and
shaking on a roto-rack for 5min. For RNA isolation, 50 µl
RNA-binding beads and 2.5ml 100% isopropanol were added,
incubated at room temperature for 5min and centrifuged at 2,000
× g for 3min. Supernatant was discarded. RNA-binding beads
were washed with 1.2ml wash solution, and transferred into a
1.5ml reaction tube. The samples were centrifuged at 16,000
× g for 30 s, and the supernatant was discarded. The RNA-
binding beads were washed twice with 750 µl wash solution
2/3. The pellet was air-dried. RNA was removed from the RNA-
binding beads using 100 µl elution solution. After centrifugation
at 16,000× g for 2min, the supernatant containing the RNA was
transferred to a new nuclease-free reaction tube, and stored at
−80◦C. The quality and yield of extracted RNA were analyzed
on a total eukaryote RNA nano chip using the 2,100 Bioanalyzer
(Agilent Technologies, Germany), and by UV spectrography
using Nanodrop 1,000 (Thermo Scientific, Germany).
RNA-seq Profiling
Poly(A)+ selected RNA libraries were prepared according to
a previously published protocol while preserving the strand
information (30).
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RNA-seq Analysis
Sequencing and Mapping
Sequencing was carried out on an Illumina Genome Analyzer
II System with 2 × 51 cycles. Raw paired-end reads in
fastq format were mapped to human reference genome (hg19)
using TopHat (v2.0.9) and Bowtie2 (v2.1.0) (31, 32), with the
following parameters for TopHat: –min-anchor-length = 8, –
splice-mismatches = 1, –min-intron-length = 40, –max-intron-
length = 1,000,000, –mate-inner-dist = 150, –solexa 1.3-quals,
–coverage-search. Only reads with MAPQ ≥ 1 were considered
for expression analysis.
RNA-seq Data Analysis
Coordinates for genes and exons were downloaded from
the Ensembl Genes 53 database using BioMart tool with
Homo sapiens genes (NCBI36) dataset. Only the intervals on
chromosomes 1–22, X, Y, M with merged overlapping exons
belonging to the same gene were used to calculate exon hits.
Any read overlapping with at least 1 bp to an exon was counted.
A custom script based on the pysam module [http://pysam.
readthedocs.org; (33)] was used to count the number of sense-
and antisense reads that overlap each exon interval by at least
one base. The strand-specific RNA-Seq protocol used herein
allowed us to include only reads belonging to the original
orientation of transcription orientation for the calculation of
exons. Gene exon RPKM values were calculated according to
exon hits and normalized against the library size (total MAPQ
≥ 1 reads) and the merged length of the coding sequence of
each gene.
Mapped reads were subjected to differential gene analysis
using Cufflinks (v2.1.1) using default parameters and UCSC hg19
reference gene annotation (34).
Exon Expression Analysis
For each sample and for each gene exon, we counted the number
of reads with an alignment overlapping the exon location.We did
not count reads with an alignment overlapping multiple exons.
We then scaled the counts ci for each exon i in a transcript as si =
ci-µ/σ, whereµ is the mean of the ci values in the transcript and σ
is their standard deviation. Then, we computed a z-score for each
exon in each of the patients, comparing the (scaled) expression
of a given exon in a patient and the reference distribution
of (scaled) expression for this exon in the control samples.
Randomized datasets were generated by random permutations of
sample labels.
Alternative Expression Analysis
We used MISO (23) version (0.5.3) to obtain transcript
ratios (PSI values) from hg19 annotation. Afterwards, in order
to detect possible genes with significantly altered transcript
isoforms we used the rasp package (https://rdrr.io/github/
isglobal-brge/rasp/f/inst/doc/rasp.pdf), a distance-based non-
parametric multivariate approach as described in Gonzalez-
Porta et al. (35) and Iglewicz and Hoaglin (16). We did not
find isoforms significantly differentially expressed between the
two groups.
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